Paratek Pharmaceuticals Inc Revenue Growth Rates (PRTK), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Paratek Pharmaceuticals Inc   (NASDAQ: PRTK)
 

PRTK's Revenue Growth by Quarter and Year

Paratek Pharmaceuticals Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

PRTK Revenue (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
4th Quarter December -
3rd Quarter September -
2nd Quarter June -
1st Quarter March 31.24
FY 31.24

PRTKs Annual Revenue
Paratek Pharmaceuticals Inc 's Revenue in the fiscal year 2022 $ 160.27 millions
Paratek Pharmaceuticals Inc 's Revenue in the fiscal year 2021 $ 130.16 millions
Paratek Pharmaceuticals Inc 's Revenue in the fiscal year 2020 $ 46.92 millions
Paratek Pharmaceuticals Inc 's Revenue in the fiscal year 2019 $ 16.54 millions
Paratek Pharmaceuticals Inc 's Revenue in the fiscal year 2018 $ 17.12 millions




PRTK Revenue first quarter 2023 Y/Y Growth Comment
Paratek Pharmaceuticals Inc reported Revenue improvement of 25.65% year on year in the first quarter 2023, to $ 31.24 millions, this is lower than Paratek Pharmaceuticals Inc 's recent average Revenue surge of 2203.62%.

Looking into first quarter 2023 results within Major Pharmaceutical Preparations industry 87 other companies have achieved higher Revenue growth. While Paratek Pharmaceuticals Inc ' s Revenue rise of 25.65% ranks overall at the positon no. 918 in the first quarter 2023.


PRTK Revenue ( Y/Y Growth %) 2023
 2022 2021 2020
4th Quarter December - 137.61 % 98.5 % 78.6 %
3rd Quarter September - 23.56 % 78.99 % 247.58 %
2nd Quarter June - -48.44 % 516.18 % 355.12 %
1st Quarter March 25.65 % 51.31 % 107.45 % 395 %
FY   - 23.12 % 177.37 % -

Financial Statements
Paratek Pharmaceuticals Inc 's first quarter 2023 Revenue $ 31.24 millions PRTK's Income Statement
Paratek Pharmaceuticals Inc 's first quarter 2022 Revenue $ 24.86 millions Quarterly PRTK's Income Statement


PRTK Revenue (Quarter on Quarter Growth %)

 2023
 2022 2021 2020
4th Quarter December - 150.12 % 30.06 % 17.28 %
3rd Quarter September - 1.92 % -57.47 % 46.41 %
2nd Quarter June - 19.23 % 249.91 % 17.8 %
1st Quarter March -58.66 % -21.82 % 2.56 % -11.71 %
FY (Year on Year)   - 23.12 % 177.37 % -


Back to PRTK Growth rate Comparisons >> Back to PRTK Growth rate Comparisons >>


Revenue first quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #88
Healthcare Sector #202
Overall #918

Revenue Y/Y Growth Statistics
High Average Low
17389.66 % 2203.62 % -99.47 %
(Dec 31 2017)   (Jun 30 2018)
Revenue first quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #88
Healthcare Sector #202
Overall #918
Revenue Y/Y Growth Statistics
High Average Low
17389.66 % 2203.62 % -99.47 %
(Dec 31 2017)   (Jun 30 2018)

Revenue by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Paratek Pharmaceuticals Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
42166.67 % 4735.04 % -99.84 %
(Dec 31 2017)  


PRTK's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2023 Paratek Pharmaceuticals Inc disclosed fall in Revenue from the fourth quarter by -58.66% to $ 31.24 millions, from $ 75.56 millions achived in the previous reporting period.

But that's not important problem, as Paratek Pharmaceuticals Inc 's Revenue generally seem to plunge in this quarter.

Within Major Pharmaceutical Preparations industry 240 other companies have achieved higher Revenue quarter on quarter growth. While Paratek Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 4026.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #241
Healthcare Sector #623
Overall #4026
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #241
Healthcare Sector #623
Overall #4026
Revenue Q/Q Growth Statistics
High Average Low
42166.67 % 4735.04 % -99.84 %
(Dec 31 2017)  


PRTK's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2023 Paratek Pharmaceuticals Inc disclosed fall in Revenue from the fourth quarter by -58.66% to $ 31.24 millions, from $ 75.56 millions achived in the previous reporting period.

But that's not important problem, as Paratek Pharmaceuticals Inc 's Revenue generally seem to plunge in this quarter.

Within Major Pharmaceutical Preparations industry 240 other companies have achieved higher Revenue quarter on quarter growth. While Paratek Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 4026.


Paratek Pharmaceuticals Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Mar 31 2023)		 12 Months Ending
(Dec 31 2022)		 12 Months Ending
(Sep 30 2022)		 12 Months Ending
(Jun 30 2022)		 12 Months Ending
(Mar 31 2022)
Cumulative Revenue 12 Months Ending $ 166.64 $ 160.27 $ 116.51 $ 110.74 $ 138.60
Y / Y Revenue Growth (TTM) 20.24 % 23.13 % 1.86 % 6.9 % 150.03 %
Year on Year Revenue Growth Overall Ranking # 216 # 110 # 1519 # 729 # 177
Seqeuential Revenue Change (TTM) 3.98 % 37.56 % 5.21 % -20.1 % 6.48 %
Seq. Revenue Growth (TTM) Overall Ranking # 2124 # 1541 # 642 # 1114 # 818


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Mar 31 2023 period, Paratek Pharmaceuticals Inc 's cumulative twelve months Revenue were $ 167 millions, company would post below average annual Revenue growth of 6.48% year on year, if the fiscal year would end at Mar 31 2023.
A slow-down in the Paratek Pharmaceuticals Inc 's Revenue growth from the 75.56% growth in Dec 31 2022.

In the Healthcare sector 66 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 110 to 216.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 124
Healthcare Sector # 67
Overall # 216

Revenue TTM Y/Y Growth Statistics
High Average Low
375.52 %
 104.94 %
-31.7 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 124
Sector # 314
S&P 500 # 2124
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Mar 31 2023 period, Paratek Pharmaceuticals Inc 's cumulative twelve months Revenue were $ 167 millions, company would post below average annual Revenue growth of -31.7% year on year, if the fiscal year would end at Mar 31 2023.
A slow-down in the Paratek Pharmaceuticals Inc 's Revenue growth from the 75.56% growth in Dec 31 2022.

In the Healthcare sector 66 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 110 to 216.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 124
Healthcare Sector # 67
Overall # 216

Revenue TTM Y/Y Growth Statistics
High Average Low
375.52 %
104.94 %
-31.7 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 124
Sector # 314
S&P 500 # 2124




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
PRTK's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue fall for the quarter ending Mar 31 2023 within Healthcare SectorY/Y Change %Revenue for the quarter ending Mar 31 2023
Lantheus Holdings Inc 44.00%$ 43.998 millions
Tela Bio Inc 43.53%$ 43.531 millions
Silk Road Medical Inc 43.22%$ 43.218 millions
Escalon Medical Corp 42.14%$ 42.141 millions
Anaptysbio Inc 41.65%$ 41.649 millions
Pro dex Inc 41.17%$ 41.166 millions
Lifeward ltd 40.41%$ 40.411 millions
Inhibikase Therapeutics Inc 40.17%$ 40.169 millions
Avita Medical Inc 39.94%$ 39.939 millions
Harmony Biosciences Holdings inc 39.63%$ 39.634 millions
Arcus Biosciences Inc 38.85%$ 38.850 millions
Xtant Medical Holdings Inc 38.46%$ 38.460 millions
Biodesix Inc 38.30%$ 38.302 millions
Halozyme Therapeutics Inc 38.25%$ 38.254 millions
The Oncology Institute Inc 38.13%$ 38.127 millions
Biocryst Pharmaceuticals Inc 37.77%$ 37.768 millions
Ufp Technologies Inc 37.21%$ 37.213 millions
Soligenix inc 36.72%$ 36.724 millions
Evofem Biosciences Inc 36.65%$ 36.650 millions
Aravive Inc 36.54%$ 36.538 millions
Zynex inc 35.67%$ 35.669 millions
Foghorn Therapeutics Inc 35.43%$ 35.434 millions
Neurocrine Biosciences Inc 35.35%$ 35.351 millions
Igc Pharma Inc 35.25%$ 35.246 millions
Prosomnus Inc 34.96%$ 34.962 millions
Orthopediatrics Corp34.89%$ 34.893 millions
Pulmonx Corporation34.77%$ 34.771 millions
Orchestra Biomed Holdings Inc 34.41%$ 34.411 millions
Zai Lab Limited34.40%$ 34.400 millions
Guardant Health Inc 33.94%$ 33.939 millions


About Paratek Pharmaceuticals Inc Revenue Growth Rates (PRTK), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Paratek Pharmaceuticals Inc (CIK 1178711).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001628280-23-027035
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Paratek Pharmaceuticals Inc ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.